Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

Traxion Sab De Cv Ord Shs > Tetra Bio-Pharma provides update on status of its Phase 3
View:
Post by TheBossCwC on Dec 09, 2017 12:06pm

Tetra Bio-Pharma provides update on status of its Phase 3

Tetra Bio-Pharma provides update on status of its Phase 3 Clinical Trial Application of Lead Drug Candidate PPP001
09 December, 2017 OTTAWA, ONTARIO -- (Marketwired) -- 12/09/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process. As such, the quality certification for the manufacturing of PPP001 will take place prior to the approval of its clinical trial protocol as Health Canada assesses its partner Aphria's operations for Good Manufacturing Practices (GMP) for pharmaceutical products. Tetra agrees to this change from Health Canada because it is in the best interest of patients.
This change in the usual CTA approval process is expected to potentially extend the review process by 30 days. Tetra continues to expect PPP001 to become the first cannabis-derived inhalation drug to receive a drug identification number (DIN) from Health Canada, as well as pharmaceutical drug status from the FDA. The phase 3 trial should therefore begin in early 2018. The Company expects this change to have only a minor impact on time to market for PPP001.
Tetra received approval for the ethics review board on November 6th and subsequently submitted a Clinical Trial Application (CTA) for its Phase 3 clinical trial in cancer patients. This trial is expected to be a landmark clinical trial and is the first of its kind, enrolling a total of 946 subjects. Dr Guy Chamberland, Tetra's Chief Scientific Officer (CSO) commented that: "a GMP certification from Health Canada's drug inspectorate is welcome as this certification will signal to the company that its manufacturing partners comply with GMP requirements for drug approval and increases the measures put in place to ensure patients' safety." Once the trial is initiated, The Company will accelerate enrolment by expanding the number of clinical sites as it aims to adhere to its target date for filing PPP001 as a prescription drug (with a drug identification number - DIN) to Health Canada.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Comment by charly90 on Dec 09, 2017 12:08pm
Like small punch in the groin
Comment by Hammertown87 on Dec 09, 2017 12:37pm
whats an extra 30 days to make it right
Comment by LeafRider on Dec 09, 2017 4:45pm
This post has been removed in accordance with Community Policy
Comment by AtownMtl on Dec 09, 2017 5:50pm
Don’t bash aphria! That’s what happens when you rely on multiple partners, aphria has been busy locking down shoppers, expansion etc.. without aph tetra would not be where it is now. you 
Comment by LeafRider on Dec 10, 2017 1:56am
This post has been removed in accordance with Community Policy
Comment by AtownMtl on Dec 10, 2017 2:18am
Sharpen up ? When I mentioned that TBP should continue ACMPR process you told me to go join Andre LOL and this coming from a guy who thought aphria had 200000 patients and tried to brush it off as a typo ! And I should sharpen up ?? 
Comment by LeafRider on Dec 10, 2017 11:07am
This post has been removed in accordance with Community Policy
Comment by LeafRider on Dec 10, 2017 11:25am
This post has been removed in accordance with Community Policy
Comment by AtownMtl on Dec 10, 2017 8:50pm
you said this 1 week ago !! be honest leaf i can post it also !!! 
Comment by AtownMtl on Dec 10, 2017 9:12pm
i can post the oil DIN conversation also ? do you remember ? you said i didn't know what i was talking about when i mentionned they should get DIN for oil ! STOP being a SHEEP ! it's ok for people to have opinions.
Comment by Bigballs1974 on Dec 09, 2017 7:36pm
 I will agree they should’ve had this done and put in place but at the same time have you ever built a business how come you’re so impatient this is a brand new industry maybe you need to take a little sit down .  Things take time and I don’t care honestly one month that’s not even really worth writing down any of these words .  Shame on you you get Deducted one demerit.  You ...more  
Comment by Bigballs1974 on Dec 09, 2017 7:44pm
I’m being silly but yes if this baby goes to .60 I’m grabbing a ton :) 100% cause long I am Sam and it’s a good investment and for everything else in life there’s ‍‍‍
Comment by JoeRoganBNN on Dec 09, 2017 8:09pm
Well Tetra had promised before 2018, now its going to be at the earliest early 2018.  Another stagnant week ahead!! Ballz, i knew i should have sold a few shares on Friday.  Never ending how i havent made any money.  Been in it for 7 or 10 months now. Oh, well, whats another 8 or 9 months. 
Comment by Bigballs1974 on Dec 09, 2017 8:29pm
Exactly disappointing I guess but making money buying and selling or just reposition and buy up more just another opportunity while there cheep.
Comment by MichelC58 on Dec 09, 2017 8:43pm
a month is nothing ... I buy more if it drops Monday
Comment by JoeRoganBNN on Dec 09, 2017 9:28pm
News released on the weekend has less of an impact than posting it on Monday morning, I find. Still, not good news, hopefully people forget about it. Lol shyt happens meh
Comment by new2mjstocks on Dec 09, 2017 9:33pm
why is it such bad news?? its a minor max 30 day delay
Comment by Shadd76 on Dec 09, 2017 10:25pm
This post has been removed in accordance with Community Policy
Comment by LeafRider on Dec 10, 2017 2:08am
This post has been removed in accordance with Community Policy
Comment by Chuck03 on Dec 10, 2017 2:40pm
The best thing about this, is that they are getting the inspections out of the way to guarantee consistency. This allows for faster approval, where Health Canada could say we need this, here is a DIN (especially when July 1st comes) in order to differentiate recreational and medinical marijuana. This is in comparison of having to wait to finish Phase 3 to then have an inspection, where if the ...more  
Comment by Catalystking519 on Dec 10, 2017 2:51pm
We have been working hand in hand with Health Canada,  anyone else notice this? Do they always make these reccomendations?  I think it bodes very well for tetra moving forward every step of the process.  We all know the end game is a DIN# and if we can continue to have excellent communication with Health Canada this can happen faster than we all thought, jmo.
Comment by TripleEm on Dec 10, 2017 8:04pm
Kinda sounds like Health Canada is the ones that are lagging.  the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process. As such, the quality certification for the manufacturing of PPP001 will take place prior to the approval of its clinical trial protocol as Health Canada assesses its partner Aphria's operations ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities